DHC earnings analysis
What we found in DHC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Diversified Healthcare Trust delivered a materially improved Q2 operating result: GAAP loss per share narrowed to $0.16 from $0.38, Normalized FFO rose to $0.16 per share from $0.08, and consolidated NOI grew 20.4% to $84.443 million. The improvement was driven by the SHOP recovery, where comparable occupancy reached 83.1% and average monthly rates reached $5,715, but reported revenue declined 4.5% to $365.387 million because of asset dispositions. Liquidity is adequate with $116.793 million of cash, no revolver borrowings and $150.000 million of revolver capacity, although sizable debt, medical-office NOI pressure and upcoming lease expirations remain material constraints.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- GAAP loss narrowed sharply year over year
- GAAP net loss narrowed to $37.419 million, or $0.16 per share, from a $91.639 million loss, or $0.38 per share, a year earlier. Sequentially, the loss per share improved from $0.18 in Q1 2026 to $0.16.
- Normalized FFO doubled
- Normalized FFO doubled to $38.896 million ($0.16 per share) from $18.572 million ($0.08 per share) in Q2 2025. FFO increased to $25.817 million from $13.577 million.
- SHOP operating recovery lifted NOI
- Consolidated NOI rose $14.311 million, or 20.4%, to $84.443 million. SHOP NOI increased $16.880 million, or 46.1%, to $53.495 million, led by comparable-property occupancy of 83.1% versus 81.5% and average monthly rates of $5,715 versus $5,380.
- Interest expense declined 27.2%
- Interest expense fell $13.843 million, or 27.2%, to $37.083 million, principally reflecting prior redemptions of higher-cost debt and lower discount accretion.
- Liquidity and credit profile improved
- Liquidity remained available: cash and cash equivalents were $116.793 million at June 30, 2026, with no revolver borrowings and $150.000 million available. Moody's upgraded the issuer rating to B3 from Caa1 in April 2026 and assigned a positive outlook.
- Medical-office leasing spreads positive
- Medical-office leasing was constructive, with 477,000 square feet leased during Q2 at a weighted-average rental-rate increase of 6.7% and a 7.1-year weighted-average lease term.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue declined on dispositions
- Total revenue declined $17.325 million, or 4.5%, year over year to $365.387 million, and was modestly below Q1 2026 revenue of $365.9 million. Dispositions reduced SHOP revenue by $28.349 million and Medical Office/Life Science revenue by $7.976 million versus comparable-property growth.
- Medical-office NOI contracted
- Medical Office and Life Science NOI declined $2.778 million, or 10.5%, to $23.709 million despite comparable-property NOI being nearly flat. The segment's consolidated occupancy was 92.2%, though comparable occupancy was 95.8%.
- Management fees and transition costs rose
- G&A rose $8.156 million, or 73.0%, to $19.333 million, including $9.993 million of estimated incentive management fees. The company also incurred $3.086 million of transaction costs related to transitioning 116 communities.
- Medical-office lease rollover and vacancies
- Near-term medical-office rollover remains meaningful: leases representing $11.566 million of annualized rental income, or 7.1% of segment annualized rental income, expire in 2026; this includes two tenants that vacated on June 30 with $6.885 million of annualized rental income.
- Leverage and refinancing-rate exposure
- Debt remains substantial, comprising $1.600 billion of senior unsecured notes, $375.000 million of senior secured notes, $327.190 million of fixed-rate mortgages and a $140.000 million floating-rate mortgage. At a fully drawn revolver, a 1-percentage-point rate increase would raise annual floating-rate interest expense to $20.994 million and reduce annual EPS by $0.09.
- No formal risk-factor update; cost pressure remains
- Item 1A states there were no material risk-factor changes from the Annual Report. Nevertheless, management flags continued variability in labor, insurance and food costs, while committing approximately $10.844 million of leasing spending over the next 12 months.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.16
- Segment
- SHOP revenue: $317.921 million, down $9.624 million (-2.9%) year over year; comparable-property resident fees rose $18.725 million (+6.6%).
- Segment
- Medical Office and Life Science Portfolio revenue: $40.116 million, down $7.940 million (-16.5%) year over year; comparable-property rental income increased $0.211 million (+0.5%).
- Segment
- All Other revenue: $7.350 million, up $0.239 million (+3.4%) year over year.
What they said about what is next.
The 10-Q provides no explicit quantitative earnings or revenue guidance. Management expects favorable senior-living supply/demand to support SHOP occupancy and performance, and expects labor, insurance and food-cost increases to moderate; it also says approximately $10.844 million of $11.022 million of leasing obligations is expected to be spent over the next 12 months.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 4, 2026
- In Q1 2026, Diversified Healthcare Trust reported revenues of $366.5 million, a decrease of 5.1% from $386.9 million in Q1 2025. EPS improved to $0.14 from a loss of $0.04 in the previous year, with operating cash flow…
- 10-K · February 24, 2026
- Diversified Healthcare Trust (DHC) positions itself as a healthcare-focused REIT with 298 properties (13 held for sale) across 33 states and D.C., emphasizing demographic tailwinds (age 65+ >20% by 2030 and age 75+…
- 10-Q · May 5, 2025
- Diversified Healthcare Trust reported total revenues of $386,864,000 for the quarter ended March 31, 2025, up $16,088,000 (+4.3%) versus $370,776,000 in Q1 2024. The company recorded a net loss of $8,986,000 (‑$0.04 per…
- 10-K · March 1, 2023
- Diversified Healthcare Trust positions itself as a healthcare-focused REIT with 379 wholly owned properties and a gross book value of real estate assets of $7.1 billion as of December 31, 2022, and emphasizes…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DHC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever